Published in Dig Dis Sci on October 01, 1992
Helicobacter pylori. Clin Microbiol Rev (1997) 9.22
Leptin secretion and leptin receptor in the human stomach. Gut (2000) 2.46
Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin. Gut (1993) 0.81
Effect of platelet-activating factor on gastrin release from cultured rabbit G-cells. Dig Dis Sci (2001) 0.81
Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med (1972) 5.38
The stomach is a source of leptin. Nature (1998) 3.33
Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol (1980) 2.90
[Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine]. C R Seances Acad Sci D (1979) 2.53
Leptin secretion and leptin receptor in the human stomach. Gut (2000) 2.46
The role of platelet-activating factor in platelet aggregation. Nature (1979) 2.37
Background and present status of research on platelet-activating factor (PAF-acether). Ann N Y Acad Sci (1981) 2.22
Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol (1979) 2.10
Structural analysis of purified platelet-activating factor by lipases. Nature (1977) 2.09
Sialic acid content and proteolytic activity in gastric juice in humans. An approach for appreciating mucus glycoprotein erosion. Dig Dis Sci (1988) 2.06
Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature (1974) 1.97
Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine (1993) 1.75
Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J Clin Invest (1979) 1.74
False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med (1997) 1.67
Controlled clinical trial of homoeopathy in postoperative ileus. Lancet (1988) 1.61
Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immun (1995) 1.60
Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet (1995) 1.59
[How to express results of 24-hour gastric pH measurement? Choice of a mode of expression in 27 healthy subjects]. Gastroenterol Clin Biol (1989) 1.51
Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest (1980) 1.50
Effect of mouse peritoneal macrophages of orally administered very high dilutions of silica. Eur J Pharmacol (1987) 1.49
Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab Invest (1979) 1.44
Duodenogastric reflux in children: measurement of phospholipids and trypsin in gastric content. J Pediatr Gastroenterol Nutr (1990) 1.44
Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J Clin Invest (1983) 1.44
Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol (1983) 1.43
Normal serum gastrin concentration in gastrinoma. Lancet (1995) 1.39
Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. J Immunol (1984) 1.34
Expression and regulation of leptin receptor proteins in afferent and efferent neurons of the vagus nerve. Eur J Neurosci (2001) 1.33
M or M-like protein gene polymorphisms in human group G streptococci. J Clin Microbiol (1995) 1.31
The immune response in NZBxNZW F1 hybrid mice. Clin Exp Immunol (1969) 1.30
Detection and characterization of circulating immune complexes by ultracentrifugation. Technical aspects. J Immunol Methods (1979) 1.30
Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut (1991) 1.28
Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome. Ann Surg (1981) 1.27
PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine. J Clin Invest (2001) 1.27
Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology (1977) 1.25
Biosynthesis of platelet-activating factor. I. Evidence for an acetyl-transferase activity in murine macrophages. Biochim Biophys Acta (1982) 1.24
Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer (1993) 1.23
Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology (2001) 1.22
Are sphincter defects the cause of anal incontinence after vaginal delivery? Results of a prospective study. Dis Colon Rectum (2000) 1.22
The human basophil degranulation test as an in vitro method for the diagnosis of allergies. Clin Allergy (1981) 1.21
Regression of inflammatory pseudotumor of the liver under conservative therapy. Dig Dis Sci (1995) 1.21
PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. Microcirc Endothelium Lymphatics (1984) 1.19
Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol (1986) 1.17
Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. Nature (1981) 1.15
Platelet activating factor (PAF-acether): total synthesis of 1-O-octadecyl 2-O-acetyl sn-glycero-3-phosphoryl choline. FEBS Lett (1980) 1.15
Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol (1981) 1.15
Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med (1997) 1.15
Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol (1980) 1.12
Cimetidine treatment of acute and chronic Zollinger-Ellison syndrome. World J Surg (1979) 1.11
Intracellular receptor for somatostatin in gastric mucosal cells: decomposition and reconstitution of somatostatin-stimulated phosphoprotein phosphatases. Proc Natl Acad Sci U S A (1982) 1.11
Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci U S A (1980) 1.11
Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery (1995) 1.10
Raised concentrations of platelet activating factor in colonic mucosa of Crohn's disease patients. Gut (1992) 1.10
Evidence for the involvement of IgE-basophil system in acute serum sickness. Clin Exp Immunol (1976) 1.10
Localization of gastrin receptors in intact isolated and separated rat fundic cells. Gastroenterology (1977) 1.09
Current approach to the management of tumoral process in patients with gastrinoma. World J Surg (1986) 1.09
Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis (2001) 1.09
In vitro immunological degranulation of human basophils is modulated by lung histamine and Apis mellifica. Br J Clin Pharmacol (1988) 1.08
Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut (1997) 1.08
The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol (1983) 1.07
Platelet-activating factor (PAF-acether) and macrophages. II. Phagocytosis-associated release of PAF-acether from rat peritoneal macrophages. Cell Immunol (1981) 1.07
Diagnosis and treatment of Zollinger-Ellison syndrome. Baillieres Clin Gastroenterol (1988) 1.07
Letter: Aggregation of human platelets by platelet-activating factor. Lancet (1975) 1.06
Heterogeneity of tbpB, the transferrin-binding protein B gene, among serogroup B Neisseria meningitidis strains of the ET-5 complex. Clin Diagn Lab Immunol (1997) 1.06
Paf-acether synthesis by Helicobacter pylori. Gut (1990) 1.06
Release of platelet-activating factor, slow-reacting substance, and vasoactive amines from isolated rat kidneys. Kidney Int (1984) 1.05
Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. Antimicrob Agents Chemother (2001) 1.05
Biosynthesis of platelet-activating factor. VI. Precursor of platelet-activating factor and acetyltransferase activity in isolated rat kidney cells. Lab Invest (1984) 1.04
Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology (1993) 1.04
Cadmium induces apoptosis in a human T cell line. Toxicology (1994) 1.04
Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption. Am J Clin Nutr (1994) 1.03
Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut (1992) 1.03
Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. Thromb Res (1982) 1.02
Evaluation of antisecretory drug therapy of Zollinger-Ellison syndrome (ZES) using 24-hour pH monitoring. Dig Dis Sci (1983) 1.02
Evidence that the histamine sensitivity and responsiveness of guinea-pig isolated trachea are modulated by epithelial prostaglandin E2 production. Br J Pharmacol (1988) 1.02
Serum and secretory IgA in axenic and holoxenic mice. J Immunol (1971) 1.02
Purification of a histamine H3 receptor negatively coupled to phosphoinositide turnover in the human gastric cell line HGT1. J Biol Chem (1992) 1.02
Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. Acta Physiol Scand (1983) 1.01
Alleles of the alpha1 immunoglobulin gene 3' enhancer control evolution of IgA nephropathy toward renal failure. Kidney Int (2000) 1.01
Effect of psyllium on gastric emptying, hunger feeling and food intake in normal volunteers: a double blind study. Eur J Clin Nutr (1998) 1.01
Successful resection of giant intrapericardial lipoma. Ann Thorac Surg (1994) 1.00
Histamine contraction of isolated human airway muscle preparations: role of prostaglandins. J Pharmacol Exp Ther (1986) 1.00
Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology (1999) 0.99
Evidence for immediate hypersensitivity phenomena in experimental autoimmune uveoretinitis. Eur J Immunol (1981) 0.98
PAF-acether and acetylhydrolase in stool of patients with Crohn's disease. Dig Dis Sci (1992) 0.98
Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol (2001) 0.98
Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology (1996) 0.98